The standard of cancer care fails the majority of patients who are then left with no alternative treatment plan. As a result, 50-80% of cancer patients are in no position to survive their cancer. Given the breadth of cancer drugs on the market today, this is simply unacceptable.

Genomic Expression developed the OneRNA® Platfrom to change this. The OneRNA® test can analyze 20,000 mRNAs from one patient sample to identify the most effective treatment for that patient. In fact, the OneRNA® test has been clinlically vallidated in breast and ovarian cancers, and is considered superior compared to traditional DNA panel diagnostics.